BioLineRx (BLRX) Research & Development (2011 - 2025)
BioLineRx's (BLRX) quarterly Research & Development came in at -$2.4 million in Q4 2025, down 30.03% year-on-year from -$3.5 million in Q4 2024, and down 41.07% quarter-over-quarter from -$1.7 million in Q3 2025.
BioLineRx (BLRX) Research & Development (2011 - 2025) Analysis & Trends
BioLineRx's Research & Development history runs 14 years deep, the most recent figure standing at -$2.4 million for Q4 2025.
- On a quarterly basis, Research & Development fell 30.03% year-over-year to -$2.4 million in Q4 2025; TTM through Dec 2025 was -$8.1 million, a 11.54% increase from a year earlier, with the FY2025 full-year figure at -$8.1 million, up 11.54% from the prior year.
- Research & Development eased to -$2.4 million in Q4 2025 per BLRX's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Research & Development topped out at $5.4 million in Q2 2022 and bottomed at -$5.1 million in Q4 2021.
- The 5-year median for Research & Development is -$2.6 million (2023), against an average of -$2.3 million.
- Across the five-year window, Research & Development tumbled 155.72% in 2023 and surged 39.88% in 2024, its largest moves.
- Year by year, Research & Development stood at -$5.1 million in 2021, then soared by 33.09% to -$3.4 million in 2022, then advanced by 9.56% to -$3.1 million in 2023, then jumped by 39.88% to -$1.9 million in 2024, then sank by 30.03% to -$2.4 million in 2025.
- Per Business Quant, the three latest BLRX Research & Development figures stand at -$2.4 million (Q4 2025), -$1.7 million (Q3 2025), and -$2.3 million (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | BioLineRx | 7.05 Bn | 7.06 Bn | 154,000.00 | -2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.43 Mn |
| Sep 30, 2025 | -1.72 Mn |
| Jun 30, 2025 | -2.33 Mn |
| Mar 31, 2025 | -1.62 Mn |
| Dec 31, 2024 | -1.87 Mn |
| Sep 30, 2024 | -2.57 Mn |
| Jun 30, 2024 | -2.23 Mn |
| Mar 31, 2024 | -2.49 Mn |
| Dec 31, 2023 | -3.10 Mn |
| Sep 30, 2023 | -2.73 Mn |
| Jun 30, 2023 | -3.01 Mn |
| Mar 31, 2023 | -3.68 Mn |
| Dec 31, 2022 | -3.43 Mn |
| Sep 30, 2022 | -4.37 Mn |
| Jun 30, 2022 | 5.40 Mn |
| Mar 31, 2022 | -4.44 Mn |
| Dec 31, 2021 | -5.13 Mn |
| Sep 30, 2021 | -4.92 Mn |
| Jun 30, 2021 | 5.14 Mn |
| Mar 31, 2021 | -4.28 Mn |